Company Profile
UroGen Pharma Stock Price, News & Analysis
- Ticker:
- URGN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Israel with U
Stock performance
45.60 USD (-1.79%)
Close
Last updated: August 6, 2026
1.29B USD
Market cap
Why the stock is moving
Following the latest company update, “UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights”, URGN closed up 16.3% at $46.43 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Uro-Oncology Franchise
UroGen Pharma develops and commercializes treatments for urothelial and other specialty cancers. Its approach combines local drug delivery with formulations intended to extend exposure within the urinary tract and provide non-surgical alternatives for patients with recurrent disease.
Commercial ZUSDURI Platform
ZUSDURI is FDA approved for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. The intravesical mitomycin product uses UroGen’s RTGel technology and anchors the company’s commercial presence in bladder cancer.
Next-Generation Mitomycin Programs
UGN-103 is a next-generation mitomycin formulation for recurrent low-grade intermediate-risk NMIBC and is advancing toward an NDA based on the Phase 3 UTOPIA trial. UGN-104 applies a related formulation strategy to low-grade upper tract urothelial carcinoma and is being studied in an ongoing Phase 3 trial.
Oncolytic Virus Expansion
UGN-501 is an investigational next-generation oncolytic virus initially planned for intravesical administration in NMIBC. The company also intends to evaluate delivery with RTGel, potentially extending local exposure and activity.
Future catalysts
Six-month durability data for UGN-103 expected in mid-2026.
UGN-501 IND submission planned for the second quarter of 2026, followed by Phase 1 initiation by year-end.
UGN-103 NDA submission planned for the second half of 2026.
Completion of enrollment in the UGN-104 Phase 3 trial expected by year-end 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: UroGen Pharma
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of UroGen Pharma (URGN)?
UroGen Pharma (URGN) most recently closed at 45.60 USD, a -1.79% move versus the previous session.
What is the market cap of UroGen Pharma (URGN)?
UroGen Pharma currently has a market capitalization of 1.29B USD on BioPharmSignal.
What does UroGen Pharma do?
Uro-Oncology Franchise UroGen Pharma develops and commercializes treatments for urothelial and other specialty cancers. Its approach combines local drug delivery with formulations intended to extend exposure within the urinary tract and provide non-surgical alternatives for patients with recurrent disease. Commercial ZUSDURI Platform ZUSDURI is FDA approved...
On which exchange is URGN stock listed?
UroGen Pharma (URGN) is associated with NASDAQ, Israel with U, Biopharma.
What is UGN-103?
Six-month durability data for UGN-103 expected in mid-2026.
Which conditions is UroGen Pharma targeting with UGN-103?
UroGen Pharma is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does UroGen Pharma describe recent progress with UGN-103?
Six-month durability data for UGN-103 expected in mid-2026.
What is UGN-104?
UGN-104 applies a related formulation strategy to low-grade upper tract urothelial carcinoma and is being studied in an ongoing Phase 3 trial.